General Information of the Disease (ID: M6ADIS0375)
Name
Vascular disorders of the liver
ICD
ICD-11: DB98
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 6 item(s) under this disease
Crosstalk ID: M6ACROT02108
m6A Regulator YTH domain-containing family protein 1 (YTHDF1)
m6A Target Methyl-CpG-binding protein 2 (MECP2)
Epigenetic Regulator Methyl-CpG-binding protein 2 (MECP2)
Regulated Target Solute carrier family 31 member 1 (SLC31A1)
Crosstalk relationship m6A → DNA modification
Crosstalk ID: M6ACROT05064
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
m6A Target Cellular tumor antigen p53 (TP53/p53)
Epigenetic Regulator Antisense of IGF2R non-protein coding RNA (AIRN)
Regulated Target Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05188
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target Collagen alpha-2(I) chain (COL1A2)
Epigenetic Regulator METTL3 binding lncRNA (MetBil)
Regulated Target Methyltransferase-like protein 3 (METTL3)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05189
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target Metalloproteinase inhibitor 1 (TIMP-1)
Epigenetic Regulator METTL3 binding lncRNA (MetBil)
Regulated Target Methyltransferase-like protein 3 (METTL3)
Crosstalk relationship ncRNA → m6A
Crosstalk ID: M6ACROT05717
m6A Regulator Methyltransferase-like 3 (METTL3)
m6A Target Growth arrest specific 5 (GAS5)
Epigenetic Regulator Growth arrest specific 5 (GAS5)
Regulated Target Dynamin-1-like protein (DRP1)
Crosstalk relationship m6A → ncRNA
Crosstalk ID: M6ACROT05718
m6A Regulator YTH domain-containing family protein 2 (YTHDF2)
m6A Target Growth arrest specific 5 (GAS5)
Epigenetic Regulator Growth arrest specific 5 (GAS5)
Regulated Target Dynamin-1-like protein (DRP1)
Crosstalk relationship m6A → ncRNA
References
Ref 1 Clinical pipeline report, company report or official report of Amgen (2009).
Ref 2 Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74. doi: 10.1038/nchembio800. Epub 2006 Jun 11.
Ref 3 US patent application no. 8,669,257, Phenazine derivatives and uses thereof as potassium channel modulators.
Ref 4 Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42. doi: 10.1182/blood-2007-08-108241. Epub 2007 Sep 17.
Ref 5 Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. PLoS One. 2014; 9(12): e113465.